Taking to the stage this week in front of an annual gathering of activist investors at New York’s Pierre Hotel, Starboard Value chief executive Jeff Smith was in a hurry to explain his latest bold bet.
After speeding through the hedge fund’s plans for software giant Salesforce and consumer drugmaker Kenvue, Smith flicked to a slide of the double-helix logo of one of America’s most venerable pharmaceutical companies.
“Anybody want to talk about Pfizer?” the 52-year-old asked with a…
Read the full article here